Panelists report that the AUGMENT-101 trial demonstrated meaningful clinical benefits of menin inhibitors in ...

Panelists discuss how robust clinical evidence from major studies like the EPIC and OPERA trials demonstrates that ...

Panelists discuss how supporting primary care providers requires moving beyond passive quality measures to peer-to-peer ...

Panelists discuss how progression independent of relapse activity (PIRA) represents a distinct pathological process involving ...

A panelist discusses how personalized ITP care requires open conversations about testing costs, insurance coverage, and ...

Panelists discuss the promising results of the ReNeu trial for mirdametinib, highlighting its significant tumor shrinkage and ...

Panelists discuss how UPMC's integrated delivery and financing system enables coordinated care through e-consults, proactive ...

The genes are all associated with cellular senescence, which is believed to play an important role in the development of ...

CK Wang, MD, chief medical officer of COTA, discusses how real-world data help identify disparities and gaps in cancer care.

Investigators used previous trial data to compare patients receiving the chimeric antigen receptor (CAR) T-cell therapy ...

Revumenib for relapsed/refractory acute leukemias with KMT2A translocation is cost-neutral for health plans, but traditional ...

As Obergefell v Hodges turns 10 years, LGBTQ+ rights face renewed threats amid political shifts, impacting health care equity ...